Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

By D. Blum, S. Torch, N. Lambeng, M. Nissou, A. Benabid, R. Sadoul, J. Verna. Progress in neurobiology, 2001

1,237 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY REVIEW WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3 (2014, positive): “Exogenous WNT-1 increased the survival of dopaminergic neurons after treatment with 6-hydroxydopamine and MPP+ (L’Episcopo et al., 2011) – neurotoxic components that are known to mimic the biochemical characteristics of Parkinson’s disease (Blum et al., 2001).”
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors (2002, background): “The synthetic heroin analog MPTP can selectively damage neurons in the nigrostriatal dopaminergic pathway and produce Parkinsonism in experimental animals (Przedborski and Jackson-Lewis, 1998; Blum et al., 2001).”
The therapeutic potential of monoamine oxidase inhibitors (2006, background): “As neuronal apoptosis involves complex chains of event”
Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP (2004, background): “Today, 6-OHDA represents one of the most common neurotoxins used in degeneration models of central catecholaminergic projections, including the nigrostriatal system, in vivo and in vitro (Ungerstedt 1968, 1976; Sachs and Jonsson 1975; Blum et al. 2001).”